Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers

Scandinavian Journal of Immunology

Volumn 69, Issue 4, 2009, Pages 374-380

  Zadura, A Foltyn ^a   Theander, E ^b   Blom, A M ^a   Trouw, L A ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BINDING PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT INHIBITOR; COMPLEMENT INHIBITOR C4B BINDING PROTEIN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SJOEGREN SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMPLEMENT C3; COMPLEMENT C4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; SJOGREN'S SYNDROME;

EID: 61849088306     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02229.x     Document Type: Article

References (32)

1. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002 61 : 554 8.
2. Strömbeck B, Ehdahl C, Manthrope R, Wikström I, Jacobsson L. Health-related quality of life in primary Sjögren′s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000 29 : 20 8.
3. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004 50 : 1262 9.
4. Theander E, Henriksson G, Ljungberg O et al. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006 65 : 796 803.
5. Jonsson RBS, Gordon T. Sjögrens′s Syndrome. In : Koopman W, Moreland L, eds. Arthritis and Allied Conditions - A Textbok of Rheumatology, 15th edn. Philadelphia : Lippincott Williams&Wilkins, 2005 : 1681 705.
6. Rischmueller M, Lester S, Chen Z et al. HLA class II phenotype controls diversification of the autoantibody response in primary Sjogren's syndrome (pSS). Clin Exp Immunol 1998 111 : 365 71.
7. Gottenberg JE, Busson M, Loiseau P et al. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 2003 48 : 2240 5.
8. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002 46 : 741 7.
9. Ramos-Casals M, Brito-Zeron P, Yague J et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford, England) 2005 44 : 89 94.
10. Blom AM, Villoutreix BO, Dahlback B. Complement inhibitor C4b-binding protein - friend or foe in the innate immune system? Mol Immunol 2004 40 : 1333 46.
11. Blom AM, Kask L, Dahlback B. CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. Mol Immunol 2003 39 : 547 56.
12. Dahlback B, Hildebrand B. Degradation of human complement component C4b in the presence of the C4b-binding protein-protein S complex. Biochem J 1983 209 : 857 63.
13. Gigli I, Fujita T, Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci USA 1979 76 : 6596 600.
14. Hillarp A, Hessing M, Dahlback B. Protein S binding in relation to the subunit composition of human C4b-binding protein. FEBS Lett 1989 259 : 53 6.
15. Pardo-Manuel F, Rey-Campos J, Hillarp A, Dahlback B, Rodriguez de Cordoba S. Human genes for the alpha and beta chains of complement C4b-binding protein are closely linked in a head-to-tail arrangement. Proc Natl Acad Sci USA 1990 87 : 4529 32.
16. Kask L, Hillarp A, Ramesh B, Dahlback B, Blom AM. Structural requirements for the intracellular subunit polymerization of the complement inhibitor C4b-binding protein. Biochemistry 2002 41 : 9349 57.
17. Criado Garcia O, Sanchez-Corral P, Rodriguez de Cordoba S. Isoforms of human C4b-binding protein. II. Differential modulation of the C4BPA and C4BPB genes by acute phase cytokines. J Immunol 1995 155 : 4037 43.
18. Webb JH, Blom AM, Dahlback B. Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol 2002 169 : 2580 6.
19. Garcia de Frutos P, Alim RI, Hardig Y, Zoller B, Dahlback B. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994 84 : 815 22.
20. Kusada-Funakoshi M, Sasaki J, Takada Y, Soji T, Arakawa K. Evidence that C4b-binding protein (proline-rich protein) is synthesized by hepatocytes. Biochem Med Metab Biol 1991 45 : 350 4.
21. Lappin DF, Whaley K. Interferon-induced transcriptional and post-transcriptional modulation of factor H and C4 binding protein synthesis in human monocytes. Biochem J 1990 271 : 767 72.
22. Moffat GJ, Tack BF. Regulation of C4b-binding protein gene expression by the acute-phase mediators tumor necrosis factor-alpha, interleukin-6, and interleukin-1. Biochemistry 1992 31 : 12376 84.
23. Lester S, McLure C, Williamson J et al. Epistasis between the MHC and the RCA alpha block in primary Sjogren syndrome. Ann Rheum Dis 2008 67 : 849 54.
24. Kask L, Trouw LA, Dahlback B, Blom AM. The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells. J Biol Chem 2004 279 : 23869 73.
25. Trouw LA, Nilsson SC, Goncalves I, Landberg G, Blom AM. C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. J Exp Med 2005 201 : 1937 48.
26. Trouw LA, Blom AM, Gasque P. Role of complement and complement regulators in the removal of apoptotic cells. Mol Immunol 2007 45 : 1199 1207.
27. Sjoberg AP, Trouw LA, McGrath FD, Hack CE, Blom AM. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol 2006 176 : 7612 20.
28. Brodeur SR, Angelini F, Bacharier LB et al. C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity 2003 18 : 837 48.
29. Vitali C, Palombi G, Baldini C et al. Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007 56 : 2223 31.
30. Bowman SJ, Sutcliffe N, Isenberg DA et al. Sjogren's Systemic Clinical Activity Index (SCAI) - a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome. Rheumatology (Oxford, England) 2007 46 : 1845 51.
31. Brandslund I, Teisner B, Hyltoft Petersen P, Svehag SE. Development and clinical application of electroimmunoassays for the direct quantification of the complement C3 split products C3c and C3d. Scand J Clin Lab Invest 1984 168 : 57 73.
32. Barnum SR, Dahlback B. C4b-binding protein, a regulatory component of the classical pathway of complement, is an acute-phase protein and is elevated in systemic lupus erythematosus. Complement Inflamm 1990 7 : 71 7.